Physician
Lakhiani, Chandan
Lakhiani, Chandan was paid $1.30M by Medicaid between Jan 2018 and Dec 2024, across 40 billing codes. Its largest line is 99213, doctor's office visit, returning patient (routine) — 42% of everything it billed.
33Billing provider infoLAKHIANI, CHANDAN
PROVIDENCE, RI 02903
PROVIDENCE, RI 02903
33aNPI1235134495assigned 06/15/2005
33bProvider typePediatrics Physician
28Total paid$1.30M
24GClaims19,232
24DCodes billed40
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Pediatrics Physician providers in Rhode Island
Rank by total paid#11 of 265
Median peer was paid$133K
This provider vs. median9.8×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 2,470 | $159K | |
| 2019 | 1,296 | $54K | |
| 2020 | 2,466 | $160K | |
| 2021 | 3,143 | $216K | |
| 2022 | 4,183 | $304K | |
| 2023 | 3,456 | $227K | |
| 2024incomplete | 2,218 | $178K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 42% | 6,202 | 5,828 | $540K |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | 9.6% | 2,105 | 1,981 | $125K |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 7.5% | 752 | 725 | $97K |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | 7.2% | 793 | 684 | $93K |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | 5.9% | 615 | 598 | $77K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 5.4% | 521 | 514 | $70K |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | 3.5% | 350 | 335 | $46K |
| 90461 | 3.1% | 761 | 687 | $40K | |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | 2.2% | 802 | 496 | $29K |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | 2.2% | 207 | 203 | $28K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | 2.1% | 936 | 906 | $27K |
| 83655 | 1.5% | 1,302 | 1,235 | $20K |
28 more codes
| 85027 | 1.4% | 1,244 | $19K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 1.1% | 170 | $15K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 1.1% | 169 | $15K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | 1.1% | 71 | $14K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 327 | $11K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 31 | $6K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 172 | $6K |
| 90472 | Immunization administration, each additional vaccine (list separately) | <1% | 132 | $3K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 40 | $3K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 47 | $2K |
| 36415 | Collection of venous blood by venipuncture | <1% | 276 | $2K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 60 | $2K |
| 90480 | <1% | 41 | $1K | |
| 99173 | <1% | 19 | $1K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 15 | $1K |
| 96127 | <1% | 37 | $1K | |
| 99460 | <1% | 15 | $735.49 | |
| 83718 | <1% | 29 | $549.99 | |
| 84460 | <1% | 29 | $433.81 | |
| 84450 | <1% | 29 | $425.65 | |
| 90686 | <1% | 824 | $411.00 | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 16 | $341.12 |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 19 | $322.55 |
| 96161 | <1% | 15 | $266.99 | |
| 82465 | <1% | 13 | $133.45 | |
| 81003 | <1% | 12 | $61.39 | |
| 90685 | <1% | 17 | $8.50 | |
| 90656 | <1% | 17 | $8.50 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.